Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- 5-FU-Based Chemotherapy Cures Some Patients with Colon Cancer
(Posted: 02/03/2009) - Researchers from the Adjuvant Colon Cancer Endpoints (ACCENT) Group used individual patient data from 18 phase III trials of adjuvant 5-FU-based chemotherapy for colon cancer to show that the regimens provide their survival benefit primarily by reducing the high risk of recurrence within the first two years after surgery, according to a study published online January 5, 2009, in the Journal of Clinical Oncology.
- Surgery Alone May Be Best for Early Endometrial Cancer
(Posted: 01/14/2009) - Results from a large international clinical trial show no evidence of benefit in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with early endometrial cancer, according to the Jan. 10, 2009, issue of the Lancet.
- Zoledronic Acid Prevents Bone Loss During Estrogen-Suppression Treatment of Breast Cancer
(Posted: 01/09/2007, Updated: 09/16/2008) - Zoledronic acid can prevent treatment-induced bone loss in premenopausal women undergoing total estrogen suppression after surgery for hormone-responsive breast cancer, according to an article published online Jan. 3, 2007, in the Journal of Clinical Oncology.
- Cetuximab (Erbitux®) Plus Chemo Extends Survival in Advanced Head and Neck Cancer
(Posted: 06/26/2007, Updated: 09/16/2008) - Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received cetuximab (Erbitux®) in addition to standard chemotherapy lived about three months longer than those receiving chemotherapy alone, according to findings presented at the 2007 ASCO meeting in Chicago.
- Bevacizumab (Avastin®) Benefits Some Patients With Advanced Kidney Cancer
(Posted: 06/20/2007, Updated: 01/22/2008) - Addition of the targeted drug bevacizumab (Avastin®) to interferon alfa staved off disease progression for significantly longer than a placebo in patients with advanced kidney cancer, according to findings presented at the 2007 ASCO meeting in Chicago.